Highest ever one-day spike as India records 1,52,879 new COVID19 cases in 24 hrs
The second phase started on March 1 where doses were administered to people above the age of 60 and those between 45 and 59 years with specific comorbidities.
New Delhi: The Union Health Ministry on Sunday said that over 1,52,879 new COVID19 cases, 90,584 discharges, and 839 deaths has been reported in the last 24 hours.
This is the fifth consecutive day when more than one lakh cases have been reported in the country.
With this, the total number of infections has reached 1,33,58,805 in India. With 839 new Covid-related deaths in the last 24 hours, the toll in the country has mounted to 1,69,275.
Currently, there are 11,08,087 active cases in the country.
As many as 90,584 people were discharged or recovered on Thursday taking the total number of recoveries to 1,20,81,443.
The previous high was recorded on Saturday when the country reported 1,45,384 fresh Covid positive cases in a single day.
According to the Indian Council of Medical Research (ICMR), 14,12,047 samples were tested for COVID-19 infection on Saturday. With this, the total samples tested in the country reached 25,66,26,850.
#COVID19 | 25,66,26,850 samples have been tested till April 10 including 14,12,047 samples tested yesterday: Indian Council of Medical Research (ICMR) pic.twitter.com/bI2DnmoQKW
— ANI (@ANI) April 11, 2021
The cumulative number of Covid-19 vaccine doses administered in India crossed the 10 crore mark and as many as 10,15,95,147 people have been vaccinated against Covid-19 in the country so far.
Meanwhile, the four-day-long ‘Tika Utsav’, a mass Covid-19 vaccine programme, has started in the country on Sunday (Jyotirao Phule’s birth anniversary) to April 14 (B R Ambedkar’s birth anniversary), following Prime Minister Narendra Modi’s call for the same
From April 2, the government started vaccinating all people above 45 years. India started its vaccination drive on January 16 with priority given to all healthcare and frontline workers in the first phase. The second phase started on March 1 where doses were administered to people above the age of 60 and those between 45 and 59 years with specific comorbidities.